Summary & Overview
HCPCS Level II J7188: Recombinant Factor VIII (Obizur) Injection, per I.U.
HCPCS Level II code J7188 denotes the injection of recombinant factor VIII (antihemophilic factor, obizur) billed per international unit. This code is used for administration of a clotting factor replacement therapy in patients with hemophilia A and is relevant across hospital inpatient and outpatient infusion settings. Nationally, biologic factor therapies represent a significant portion of high-cost medication spend for bleeding disorders and are central to coverage, utilization management, and specialty pharmacy arrangements.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for J7188, typical sites of service, and payer coverage considerations. The publication outlines benchmarks for utilization and cost (where available), common billing and coding considerations tied to HCPCS Level II administration codes, and recent policy updates affecting access and prior authorization processes.
The report explains what providers and billing teams need to document on service lines for factor replacement therapy, clarifies where data is not available in the input, and highlights operational implications for hospitals and infusion centers handling high-cost injectable biologics. Data-driven tables and payer policy excerpts are included to inform revenue cycle and clinical supply planning.
Billing Code Overview
HCPCS Level II code J7188 describes an injection of recombinant factor VIII (antihemophilic factor, obizur) billed per international unit (I.U.). This code represents a biologic therapeutic product used for replacement therapy in patients with hemophilia A who require factor VIII concentrate. The service type is a medication administration of a clotting factor concentrate, and the typical site of service is hospital inpatient, hospital outpatient infusion center, or infusion suite where parenteral biologic therapies are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with severe hemophilia A presents to an infusion center for scheduled prophylactic factor replacement prior to a weekend of increased physical activity. The patient receives recombinant antihemophilic factor (obizur) administered intravenously by a registered nurse. Pre-infusion workflow includes review of weight and recent factor trough levels, verification of patient identity and consent, medication reconciliation to confirm clotting factor product and unit dosing, and venous access assessment. During the visit, vital signs are documented, the calculated international unit (IU) dose is prepared using manufacturer and pharmacy labeling, and the dose is administered via slow IV push or infusion per product instructions. Post-infusion monitoring for infusion reactions is performed for 15–30 minutes, and the dose in IUs is recorded in the medication administration record and the claim using J7188 with any applicable modifier(s). Typical sites of service include hospital outpatient infusion centers, ambulatory infusion clinics, hematology specialty clinics, or home infusion when documented and billed appropriately. Common clinical workflows also include coordination with the patient’s hemophilia treatment center for ongoing dosing adjustments and documentation of bleed events or surgical prophylaxis plans when relevant.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |